



fermion

CONTACT: Kelly Tilyard, PharmaCore
Phone: 336-841-5250, ext. 101
Fax: 336-841-5251
Email: ktilyard@pharmacore.com
Web site: www.pharmacore.com

For Immediate Release

PHARMACORE ANNOUNCES CUSTOM MANUFACTURING ALLIANCE WITH FERMION

(High Point, NC) February 11, 2010 –[PharmaCore, Inc.](http://www.pharmacore.com), an experienced U.S.-based custom research organization, announces a partnership with Fermion, a subsidiary of Orion Corporation in Finland, to provide large volume manufacturing for drug development products in the global pharmaceutical market.

PharmaCore can now transfer chemical manufacturing technology directly to Fermion for projects requiring greater plant capacity. Currently, PharmaCore has the capability to develop and manufacture active ingredients from the small-molecule medicinal chemistry stage to a scale of approximately 100 kilograms in their GMP facility. The new alliance will allow PharmaCore customers to utilize Fermion's full-scale manufacturing capacity and expertise for projects advancing into Phase III and commercial programs. This partnership will provide an established communication framework and clear template for technology transfer, ensuring that knowledge gained during laboratory and pilot plant development is retained and utilized.

"We have formed long business relationships with many of our customers, synthesizing first batches for toxicology and continuing through lab process development and ultimately providing GMP material for clinical trials," said Brian Swierenga, PharmaCore's vice president of GMP operations. "Our customers already benefit from the seamless movement of their projects from med-chem through GMP pilot plant production. This new alliance with Fermion Oy allows us to extend our hard-earned experience and continue our relationship into the critical full-scale manufacturing stage of customer projects."

"PharmaCore plays an important role in our "three-prong"-approach for drug product development, as we want to offer our customers co-operation scenarios in small-scale cGMP production, contract manufacturing of dosage forms and in-licensing scenarios," said Hanspeter Ros, vice president for contract research and manufacturing services at Fermion. "We have scaled up projects up to batch sizes exceeding 1000 kg and achieved annual volumes higher than 100 tons. Together with PharmaCore we hope to offer our customer a seamless network of manufacturing services on all scales needed."

About PharmaCore

PharmaCore®, Inc., headquartered in High Point, NC, is an industry leader in custom organic synthesis, using diverse chemistries to produce pharmaceutical intermediates and APIs. The company's business offerings consist of a variety of chemistry outsourcing functions, including: medicinal chemistry services; chemical process and development; cGMP scale-up; and GMP

-MORE-



**PHARMACORE ANNOUNCES
CUSTOM MANUFACTURING
ALLIANCE WITH FERMION: Page 2
of 2**

analytical services. PharmaCore has served customers globally since 2000. Additional information is available at www.pharmacore.com.

About Fermion

Fermion is a division of Orion Corporation. Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.

-END-